Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Recommendation of “Buy” by Analysts

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have received a consensus recommendation of “Buy” from the twelve analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $44.00.

Several analysts recently weighed in on DMRA shares. Wedbush lifted their price target on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, July 30th. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a “buy” rating and a $50.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Finally, HC Wainwright restated a “buy” rating and issued a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors have recently bought and sold shares of the business. Ikarian Capital LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $6,574,000. Boothbay Fund Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $2,204,000. Jain Global LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $2,774,000. Remedium Capital Partners LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $2,772,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $266,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of DMRA opened at $30.62 on Wednesday. The firm has a market cap of $1.89 billion, a P/E ratio of -9.09 and a beta of 1.47. Damora Therapeutics, Inc. Common Stock has a 52 week low of $2.45 and a 52 week high of $38.33. The firm’s 50-day simple moving average is $28.70 and its 200 day simple moving average is $26.67.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.06. As a group, equities analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.98 earnings per share for the current year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.